Biodesix Q2 revenue rises 34%, beats analyst estimates

Biodesix

05/08/2026 21:24

Overview
U.S. diagnostic solutions firm's Q2 revenue rose 34% yr/yr, beating analyst expectations
Company posted 82% gross margin, up 200 basis points from prior year
Net loss for Q2 narrowed 37% yr/yr to $7.3 mln

Outlook
Biodesix maintains FY 2026 revenue guidance at $108-114 mln, midpoint reflects 25% growth
Company expects to maintain gross margin of about 80% for FY 2026
Biodesix expects continued improvement in adjusted EBITDA on path to profitability

Result Drivers
DIAGNOSTIC TESTING GROWTH - Co said 42% growth in diagnostic testing revenue was driven by a 38% increase in test volumes and higher average revenue per test
REIMBURSEMENT & SALES FORCE - Co attributed performance to expanded reimbursement coverage and improved sales force productivity
GROSS MARGIN IMPROVEMENT - Co said higher diagnostic testing volumes, improved average revenue per test, and lab workflow optimization led to higher gross margin

Company press release: ID:nGNX8KLTCZ

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$26.86 mln
$26.03 mln (7 Analysts)
Q2 Net Loss
 
$7.27 mln
 
Q2 Operating Expenses
 
$32.25 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Biodesix Inc is $28.50, about 25.2% above its August 4 closing price of $22.76

Reuters Recommended Reads
Aug 4 - Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage
Aug 4 - Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Aug 4 - Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)